Stallergenes Greer

Stallergenes Greer
Public (Euronext: STAGR)
Founded 2015
Headquarters London, United Kingdom
Key people
 Fereydoun Firouz (Chief Executive Officer)
Peter Bühler (Chief Financial Officer)
Revenue Increase € 186.4 million (2016) [1]
Number of employees
 > 1,400
Website www.stallergenesgreer.com/ Edit this on Wikidata

Stallergenes Greer plc is a global biopharmaceutical company headquartered in London, specializing in the diagnosis and treatment of respiratory allergies through immunotherapy.

Stallergenes Greer plc is the parent company of GREER Laboratories, Inc.[2] (registered office is in the U.S.) and Stallergenes S.A.S. (registered office in France).[3]

History

Stallergenes, established 1962,[4] was a French pharmaceutical company headquartered in Antony, Hauts-de-Seine. The founder was Institut Mérieux in Lyon (France). In 2015 Stallergenes, previously headquartered in Antony, Hauts-de-Seine, and U.S. Greer Laboratories, Inc. merged to form Stallergenes Greer headquartered in London, "a worldwide leader in allergy immunotherapy".[5][6]

Greer dates was founded by R.T. Greer, a collecter of source materials (i.e. : roots, herbs, pollens) in 1904.[7]

Executive committee

The board of directors includes:[8]

  • Fereydoun Firouz Chairman & CEO Executive Director
  • Jean-Luc Belingard Independent Director
  • Rodolfo Bogni Director
  • Patrick Langlois Independent Director
  • Stefan Meister Director
  • Paola Ricci Executive Director, Head of Pharmaceutical Affairs
  • Yvonne Schlaeppi Independent Director
  • Elmar Schnee Independent Director


Previous CEOs of Stallergenes include Michele Antonelli and Christian Chavy.

A pharmaceutical and clinical development programme

Since 2003, Stallergenes has been involved in a clinical development programme whose objective is to develop proprietary medicines intended to cover the main allergens responsible for more than 80% of respiratory allergies around the world.

Oralair is the first sublingual immunotherapy tablet resulting from this programme. Oralair is marketed in 22 countries and has been approved by the Food and Drug Administration in the United States.

The second project in this programme is the house dust mite immunotherapy tablet:

Three other projects intended for the treatment of allergic rhinitis caused by birch pollen, Japanese cedar and ragweed pollen are currently under development.

References

  1. ↑ "Annual report" (PDF). stallergenesgreer.com. 2016.
  2. ↑ "Stallergenes Greer - Life beyond allergy". Stallergenes Greer.
  3. ↑ "LinkedIn". www.linkedin.com.
  4. ↑ "Linked In: Stallergenes".
  5. ↑ "About Us - stallergenesgreer.com". www.stallergenesgreer.com.
  6. ↑ "Stallergenes and Greer to create the World Leader in Allergy Immunotherapy - Labiotech.eu". 30 June 2015.
  7. ↑ "History - stallergenesgreer.com". stallergenesgreer.com.
  8. ↑
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.